The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels: A Systematic Review and Meta-analysis
Open accessAbstract
Importance: High blood pressure (BP) is the most important risk factor for death and cardiovascular disease (CVD) worldwide. The optimal cutoff for treatment of high BP is debated. Objective: To assess the association between BP lowering treatment and death and CVD at different BP levels. Data Sources: Previous systematic reviews were identified from PubMed, the Cochrane Database of Systematic Reviews, and the Database of Abstracts of Reviews of Effect. Reference lists of these reviews were searched for randomized clinical trials. Randomized clinical trials published after November 1, 2015, were also searched for in PubMed and the Cochrane Central Register for Controlled Trials during February 2017. Study Selection: Randomized clinical trials with at least 1000 patient-years of follow-up, comparing BP-lowering drugs vs placebo or different BP goals were included. Data Extraction and Synthesis: Data were extracted from original publications. Risk of bias was assessed using the Cochrane Collaborations assessment tool. Relative risks (RRs) were pooled in random-effects meta-analyses with Knapp-Hartung modification. Results are reported according to PRISMA guidelines. Main Outcomes and Measures: Prespecified outcomes of interest were all-cause mortality, cardiovascular mortality, major cardiovascular events, coronary heart disease (CHD), stroke, heart failure, and end-stage renal disease. Results: Seventy-four unique trials, representing 306 273 unique participants (39.9% women and 60.1% men; mean age, 63.6 years) and 1.2 million person-years, were included in the meta-analyses. In primary prevention, the association of BP-lowering treatment with major cardiovascular events was dependent on baseline systolic BP (SBP). In trials with baseline SBP 160 mm Hg or above, treatment was associated with reduced risk for death (RR, 0.93; 95% CI, 0.87-1.00) and a substantial reduction of major cardiovascular events (RR, 0.78; 95% CI, 0.70-0.87). If baseline SBP ranged from 140 to 159 mm Hg, the association of treatment with mortality was similar (RR, 0.87; 95% CI, 0.75-1.00), but the association with major cardiovascular events was less pronounced (RR, 0.88; 95% CI, 0.80-0.96). In trials with baseline SBP below 140 mm Hg, treatment was not associated with mortality (RR, 0.98; 95% CI, 0.90-1.06) and major cardiovascular events (RR, 0.97; 95% CI, 0.90-1.04). In trials including people with previous CHD and mean baseline SBP of 138 mm Hg, treatment was associated with reduced risk for major cardiovascular events (RR, 0.90; 95% CI, 0.84-0.97), but was not associated with survival (RR, 0.98; 95% CI, 0.89-1.07). Conclusions and Relevance: Primary preventive BP lowering is associated with reduced risk for death and CVD if baseline SBP is 140 mm Hg or higher. At lower BP levels, treatment is not associated with any benefit in primary prevention but might offer additional protection in patients with CHD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., de Ferranti, S. D., Floyd, J., Fornage, M., Gillespie, C., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000485 · Cited by 12,591
Lim, S. S., Vos, T., Flaxman, A. D., Danaei, G., Shibuya, K., Adair-Rohani, H., AlMazroa, M. A., Amann, M., Anderson, H. R., Andrews, K. G., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61766-8 · Cited by 11,805
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Sterne, J. A. C., Sutton, A. J., Ioannidis, J. P. A., Terrin, N., Jones, D. R., Lau, J., Carpenter, J., Rucker, G., Harbord, R. M., Schmid, C. H., et al. (2011) · BMJ · doi:10.1136/bmj.d4002 · Cited by 7,709
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs104 · Cited by 6,879
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 6,094
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
Hebert, L. A., Parikh, S., Prosek, J., Nadasdy, T., & Rovin, B. H. (2013) · American Journal of Nephrology · doi:10.1159/000354390 · Cited by 4,376
Ettehad, D., Emdin, C. A., Kiran, A., Anderson, S. G., Callender, T., Emberson, J., Chalmers, J., Rodgers, A., & Rahimi, K. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01225-8 · Cited by 3,755
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
Treatment of hypertension in patients 80 years of age or older
Beckett, N. S., Peters, R., Fletcher, A. E., Staessen, J. A., Liu, L., Dumitrascu, D., Stoyanovsky, V., Antikainen, R. L., Nikitin, Y., Anderson, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801369 · Cited by 3,092
Staessen, J. A., Fagard, R., Thijs, L., Celis, H., Arabidze, G. G., Birkenhäger, W. H., Bulpitt, C. J., de Leeuw, P. W., Dollery, C. T., Fletcher, A. E., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)05381-6 · Cited by 2,989
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
Law, M. R., Morris, J. K., & Wald, N. J. (2009) · BMJ · doi:10.1136/bmj.b1665 · Cited by 2,775
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Parving, H., Lehnert, H., Brøchner‐Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · PubMed · Cited by 2,535
Klahr, S., Levey, A. S., Beck, G. J., Caggiula, A. W., Hunsicker, L., Kusek, J. W., & Striker, G. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403313301301 · Cited by 2,328
A modified test for small‐study effects in meta‐analyses of controlled trials with binary endpoints
Harbord, R. M., Egger, M., & Sterne, J. A. C. (2006) · Statistics in Medicine · doi:10.1002/sim.2380 · Cited by 2,267
Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
Dahlöf, B., Hansson, L., Lindholm, L. H., Scherstén, B., Ekbom, T., & Wester, P.-O. (1991) · The Lancet · doi:10.1016/0140-6736(91)92589-t · Cited by 1,881
Maschio, G., Alberti, D., Janin, G., Locatelli, F., Mann, J. F. E., Motolese, M., Ponticelli, C., Ritz, E., & Zucchelli, P. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341502 · Cited by 1,766
Industry sponsorship and research outcome
Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B., & Bero, L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000033.pub3 · Cited by 1,697
The J-Curve Phenomenon in Hypertension
Kang, Y.-Y., & Wang, J.-G. (2016) · Pulse · doi:10.1159/000446922 · Cited by 1,530
Kinaan, M., Ding, H., & Triggle, C. R. (2015) · Medical Principles and Practice · doi:10.1159/000381643 · Cited by 1,515
AMERY, A. (1985) · The Lancet · doi:10.1016/s0140-6736(85)91783-0 · Cited by 1,476
Lithell, H., Hansson, L., Skoog, I., Elmfeldt, D., Hofman, A., Olofsson, B., Trenkwalder, P., & Zanchetti, A. (2003) · Journal of Hypertension · doi:10.1097/00004872-200305000-00011 · Cited by 1,409
Medical Research Council trial of treatment of hypertension in older adults: principal results.
Peart, S., Brennan, P. J., Broughton, P., Dollery, C. T., Hudson, M. F., Lever, A. F., Meade, T. W., Rose, G., & Pocock, S. (1992) · Cited by 1,360
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208799 · Cited by 1,319
Combined angiotensin inhibition for the treatment of diabetic nephropathy
Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303154 · Cited by 1,169
Nissen, S. E., Tuzcu, E. M., Libby, P., Thompson, P. D., Ghali, M., Garza, D., Berman, L., Shi, H., Buebendorf, E., Topol, E. J., et al. (2004) · JAMA · doi:10.1001/jama.292.18.2217 · Cited by 1,154
Angiotensin-converting-enzyme inhibition in stable coronary artery disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa042739 · Cited by 1,123
Preventing Microalbuminuria in Type 2 Diabetes
Ruggenenti, P., Fassi, A., Ilieva, A. P., Bruno, S., Iliev, I. P., Brusegan, V., Rubis, N., Gherardi, G., Arnoldi, F., Ganeva, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042167 · Cited by 1,020
Neaton, J. D. (1993) · JAMA · doi:10.1001/jama.270.6.713 · Cited by 946
Schrier, R. W., Estacio, R. O., Esler, A., & Mehler, P. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00213.x · Cited by 851
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
Yusuf, S., Bosch, J., Dagenais, G., Zhu, J., Xavier, D., Liu, L., Pais, P., López-Jaramillo, P., Leiter, L. A., Dans, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1600176 · Cited by 848
Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes
Haller, H., Ito, S., Izzo, J. L., Januszewicz, A., Katayama, S., Menne, J., Mimran, A., Rabelink, T. J., Ritz, E., Ruilope, L. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007994 · Cited by 792
Renal and retinal effects of enalapril and losartan in type 1 diabetes
Mauer, M., Zinman, B., Gardiner, R., Suissa, S., Sinaiko, A., Strand, T., Drummond, K., Donnelly, S., Goodyer, P., Gubler, M. C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808400 · Cited by 791
Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events
Yusuf, S., Diener, H.-C., Sacco, R. L., Cotton, D., Ôunpuu, S., Lawton, W. A., Palesch, Y., Martin, R. H., Albers, G. W., Bath, P., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804593 · Cited by 785
Bundy, J. D., Li, C., Stuchlik, P., Bu, X., Kelly, T. N., Mills, K. T., He, H., Chen, J., Whelton, P. K., & He, J. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.1421 · Cited by 783
Lv, J., Neal, B., Ehteshami, P., Ninomiya, T., Woodward, M., Rodgers, A., Wang, H., MacMahon, S., Turnbull, F., Hillis, G., et al. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001293 · Cited by 777
Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial
(2013) · The Lancet · doi:10.1016/s0140-6736(13)60852-1 · Cited by 749
Effect of ramipril on the incidence of diabetes
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa065061 · Cited by 737
Randomised trial of treatment of hypertension in elderly patients in primary care.
Coope, J., & Warrender, T. S. (1986) · BMJ · doi:10.1136/bmj.293.6555.1145 · Cited by 725
(2000) · PubMed · Cited by 691
Weber, M. A., Schiffrin, E. L., White, W. B., Mann, S., Lindholm, L. H., Kenerson, J. G., Flack, J. M., Carter, B. L., Materson, B. J., Ram, C. V. S., et al. (2014) · Journal of Hypertension · doi:10.1097/hjh.0000000000000065 · Cited by 683
Effect of Amlodipine on the Progression of Atherosclerosis and the Occurrence of Clinical Events
Pitt, B., Byington, R. P., Furberg, C. D., Hunninghake, D. B., Mancini, G. B. J., Miller, M. E., Riley, W., & (for the PREVENT Investigators) (2000) · Circulation · doi:10.1161/01.cir.102.13.1503 · Cited by 669
Effect of valsartan on the incidence of diabetes and cardiovascular events
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001121 · Cited by 660
Treatment of mild hypertension: A five year controlled drug trial
Helgeland, A. (1980) · The American Journal of Medicine · doi:10.1016/0002-9343(80)90438-6 · Cited by 638
Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease
Lonn, E. M., Bosch, J., López-Jaramillo, P., Zhu, J., Liu, L., Pais, P., Diaz, R., Xavier, D., Sliwa, K., Dans, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1600175 · Cited by 618
(1970) · JAMA · doi:10.1001/jama.213.7.1143 · Cited by 554
Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria
Asselbergs, F. W., Diercks, G. F. H., Hillege, H. L., van Boven, A. J., Janssen, W. M. T., Voors, A. A., de Zeeuw, D., de Jong, P. E., van Veldhuisen, D. J., & van Gilst, W. H. (2004) · Circulation · doi:10.1161/01.cir.0000146378.65439.7a · Cited by 523
Chaturvedi, N. (1997) · The Lancet · doi:10.1016/s0140-6736(96)10244-0 · Cited by 518
Poole-Wilson, P. A., Lubsen, J., Kirwan, B.-A., van Dalen, F. J., Wagener, G., Danchin, N., Just, H., Fox, K. A., Pocock, S. J., Clayton, T. C., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16980-8 · Cited by 511
Random-Effects Meta-analysis of Inconsistent Effects: A Time for Change
Cornell, J. E., Mulrow, C. D., Localio, R., Stack, C. B., Meibohm, A. R., Guallar, E., & Goodman, S. N. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2886 · Cited by 453
Verdecchia, P., Staessen, J. A., Angeli, F., de Simone, G., Achilli, A., Ganau, A., Mureddu, G., Pede, S., Maggioni, A. P., Lucci, D., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61340-4 · Cited by 434
Shanghai trial of nifedipine in the elderly
Gong, L., Zhang, W., Zhu, Y., Zhu, J., kong, D., Pag??, V., Ghadirian, P., LeLorier, J., & Hamet, P. (1996) · Journal of Hypertension · doi:10.1097/00004872-199610000-00013 · Cited by 412
JATOS Study Group (2008) · Hypertension Research · doi:10.1291/hypres.31.2115 · Cited by 397
Liu, L., Zhang, Y., Liu, G., Li, W., Zhang, X., & Zanchetti, A. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000194120.42722.ac · Cited by 392
Ravid, M., Brosh, D., Levi, Z., Bar-Dayan, Y., Ravid, D., & Rachmani, R. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_1-199806150-00004 · Cited by 389
Brunström, M., & Carlberg, B. (2016) · BMJ · doi:10.1136/bmj.i717 · Cited by 375
Self-citationOgihara, T., Saruta, T., Rakugi, H., Matsuoka, H., Shimamoto, K., Shimada, K., Imai, Y., Kikuchi, K., Ito, S., Eto, T., et al. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.146035 · Cited by 371
Hedblad, B., Wikstrand, J., Janzon, L., Wedel, H., & Berglund, G. (2001) · Circulation · doi:10.1161/01.cir.103.13.1721 · Cited by 325
Thomopoulos, C., Parati, G., & Zanchetti, A. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000000881 · Cited by 298
Results of the pilot study for the Hypertension in the Very Elderly Trial
Bulpitt, C. J., Beckett, N. S., Cooke, J., Dumitrascu, D. L., Gil-Extremera, B., Nachev, C., Nunes, M., Peters, R., Staessen, J. A., & Thijs, L. (2003) · Journal of Hypertension · doi:10.1097/00004872-200312000-00030 · Cited by 296
Marre, M., Lievre, M., Chatellier, G., Mann, J. F. E., Passa, P., & Ménard, J. (2004) · BMJ · doi:10.1136/bmj.37970.629537.0d · Cited by 296
Thomopoulos, C., Parati, G., & Zanchetti, A. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000447 · Cited by 275
Teo, K. K., Burton, J. R., Buller, C. E., Plante, S., Catellier, D., Tymchak, W., Dzavik, V., Taylor, D., Yokoyama, S., & Montague, T. J. (2000) · Circulation · doi:10.1161/01.cir.102.15.1748 · Cited by 275
Bilous, R., Chaturvedi, N., Sjølie, A. K., Fuller, J., Klein, R., Orchard, T., Porta, M., & Parving, H.-H. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-1-200907070-00120 · Cited by 252
Irbesartan in Patients with Atrial Fibrillation
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008816 · Cited by 249
for the ORIENT study investigators, Imai, E., Chan, J. C. N., Ito, S., Yamasaki, T., Kobayashi, F., Haneda, M., & Makino, H. (2011) · Diabetologia · doi:10.1007/s00125-011-2325-z · Cited by 236
MacMahon, S., Sharpe, N., Gamble, G., Clague, A., Ni Mhurchu, C., Clark, T., Hart, H., Scott, J., & White, H. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00736-1 · Cited by 235
Pitt, B., O’Neill, B., Feldman, R., Ferrari, R., Schwartz, L., Mudra, H., Bass, T., Pepine, C., Texter, M., Haber, H., et al. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01461-8 · Cited by 231
Lüders, S., Schrader, J., Berger, J., Unger, T., Zidek, W., Böhm, M., Middeke, M., Motz, W., Lübcke, C., Gansz, A., et al. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e3282ff8864 · Cited by 229
The Australian therapeutic trial in mild hypertension. Report by the Management Committee.
(1980) · PubMed · Cited by 215
Kjeldsen, S. E., Lund-Johansen, P., Nilsson, P. M., & Mancia, G. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07257 · Cited by 208
Suzuki, H., Kanno, Y., Sugahara, S., Ikeda, N., Shoda, J., Takenaka, T., Inoue, T., & Araki, R. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.04.031 · Cited by 191
for the Post-stroke Antihypertensive Treatment Study (PATS) Investigators, Liu, L., Wang, Z., Gong, L., Zhang, Y., Thijs, L., Staessen, J. A., & Wang, J. (2009) · Hypertension Research · doi:10.1038/hr.2009.139 · Cited by 189
on behalf of Hypertension Objective Treatment Based on Measurement by Electrical Devices of Blood Pressure (HOMED-BP) investigators, Asayama, K., Ohkubo, T., Metoki, H., Obara, T., Inoue, R., Kikuya, M., Thijs, L., Staessen, J. A., & Imai, Y. (2012) · Hypertension Research · doi:10.1038/hr.2012.125 · Cited by 186
Rouleau, J. L., Warnica, W. J., Baillot, R., Block, P. J., Chocron, S., Johnstone, D., Myers, M. G., Calciu, C.-D., Dalle-Ave, S., Martineau, P., et al. (2008) · Circulation · doi:10.1161/circulationaha.106.685073 · Cited by 158
Filipovský, J., Seidlerová, J., Kratochvíl, Z., Karnosová, P., Hronová, M., & Mayer, O. (2016) · Blood Pressure · doi:10.3109/08037051.2015.1134086 · Cited by 152
Atenolol in Secondary Prevention after Stroke
Eriksson, S., Olofsson, B., & Wester, P. (1995) · Cerebrovascular Diseases · doi:10.1159/000107813 · Cited by 142
Redefining Blood-Pressure Targets — SPRINT Starts the Marathon
Perkovic, V., & Rodgers, A. (2015) · New England Journal of Medicine · doi:10.1056/nejme1513301 · Cited by 136
Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) pilot study.
Perry, H. M., Smith, W. M., McDonald, R. H., Black, D. M., Cutler, J. A., Furberg, C. D., Greenlick, M. R., Kuller, L. H., Schnaper, H. W., & Schoenberger, J. A. (1989) · Stroke · doi:10.1161/01.str.20.1.4 · Cited by 129
Ruggenenti, P. L., Lauria, G., Iliev, I. P., Fassi, A., Parvanova, A. I., Rota, S., Chiurchiu, C. R., Barlovič, D. P., Sghirlanzoni, A., Lombardi, R., et al. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.174474 · Cited by 104
Fogari, R., Preti, P., Zoppi, A., Rinaldi, A., Corradi, L., Pasotti, C., Poletti, L., Marasi, G., Derosa, G., Mugellini, A., et al. (2002) · American Journal of Hypertension · doi:10.1016/s0895-7061(02)03017-0 · Cited by 98
Effects of Intensive Antihypertensive Treatment on Chinese Hypertensive Patients Older Than 70 Years
Wei, Y. Q., Jin, Z., Shen, G., Zhao, X., Yang, W.-H., ye, Z., & Wang, J. (2013) · Journal of Clinical Hypertension · doi:10.1111/jch.12094 · Cited by 93
Ruggenenti, P. L., Fassi, A., Parvanova, A. I., Iliev, I. P., Chiurchiu, C. R., Rubis, N., Gherardi, G., Ene‐Iordache, B., Gaspari, F., Perna, A., et al. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e32834069bd · Cited by 85
Fuchs, S. C. P. C., Poli‐de‐Figueiredo, C. E., Neto, J. A. D. F., Scala, L. C. N., Whelton, P. K., Mosele, F., de Mello, R. G. B., Vilela-Martin, J. F., Moreira, L. B., Chaves, H., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.004248 · Cited by 77
Langford, H. G., Stamier, J., Wassertheil-Smoller, S. W., & Prineas, R. J. (1986) · Progress in Cardiovascular Diseases · doi:10.1016/0033-0620(86)90033-2 · Cited by 73
Hansson, L. (1994) · Blood Pressure · doi:10.3109/08037059409102265 · Cited by 65
Dens, J., Desmet, W. J., Coussement, P., Scheerder, I. K. D., Kostopoulos, K., Kerdsinchai, P., Supanantaroek, C., & Piessens, J. (2003) · Heart · doi:10.1136/heart.89.8.887 · Cited by 47
Herlitz, J. D. (1995) · Borås Academic Digital Archive (University of Borås) · Cited by 36
Tillin, T., Orchard, T. J., Malm, A. R., Fuller, J., & Chaturvedi, N. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283480db9 · Cited by 26
[Prevention and treatment of stroke after hypertension for ten years in Hunan Province].
Sun, M., Zhou, H., & Jia, Z. (1997) · PubMed · Cited by 13
Brunström, M., & Carlberg, B. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001574 · Cited by 10
Self-citation
Cited by
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286
Self-citationMancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
Self-citationWilliams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001940 · Cited by 2,885
2024 ESC Guidelines for the management of elevated blood pressure and hypertension
McEvoy, J. W., McCarthy, C. P., Bruno, R. M., Brouwers, S., Canavan, M. D., Ceconi, C., Christodorescu, R. M., Daskalopoulou, S. S., Ferro, C. J., Gerdts, E., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae178 · Cited by 2,298
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
Metadata
- Authors
- Brunström, M., & Carlberg, B.
- Venue
- JAMA Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2018-01-01
- Volume
- 178
- Issue
- 1
- Pages
- 28
- ISSN
- 2168-6106 (ISSN-L)
- OpenAlex
- W2769574669
- Cited by
- 471
- References
- 117
- FWCI
- 27.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.